What is Lu PSMA (Lutetium-Prostate Specific Membrane Antigen) Therapy?

Lu177 PSMA Therapy is a treatment for patients with prostate cancer, especially those who have become refractory to conventional therapy. Lutetium PSMA therapy helps to slow down the growth of the cancer cells, reduce the size of the tumours and most importantly improve the quality of life of the patients by reducing the pain caused by the cancer.

Many prostate cancers, in particular those that have spread or become resistant to hormonal therapies, express a unique receptor on their cell surface called Prostate Specific Membrane Antigen (PSMA). When Prostate Cancer metastasizes i.e. spreads to other parts of the body, the PSMA receptor is expressed over the sites of metastases as well.

How does Lu PSMA Therapy Work?

Lutetium-177 is a radioactive substance that emits beta radiation, a destructive kind of radiation. Lutetium-177 is bound to a small peptide which attaches to the PSMA receptor expressed on the cancer cell surface. The Lutetium 177 – PSMA complex, thus attached to the prostate cancer cell, then emits killing radiation causing cell death of the cancer cell. Since the penetration of the emitted beta particle is very small, the surrounding normal cells are spared.

How is the Therapy Done?

Lu177 PSMA is administered intravenously. The patient is admitted to the hospital for 24 hours. A kidney function scan called a MAG3/EC scan is done prior to the administration of the Lu177 PSMA.

What are the Side Effects of Lu PSMA Therapy?

Lu177 PSMA is well tolerated. The most common side effects are a slightly dry mouth, fatigue and nausea. There may also be a slight fall in the white blood cells and platelets about 2 – 3 weeks after the Lu177 PSMA administration.

What is the Response Rate With Lu PSMA Therapy?

The response rates of Lu177 PSMA depend on the tumour biology of prostate cancer, the initial Gleason Score, the extent of disease and the responses to prior therapies. Typically, more than 70% of patients demonstrate a reduction in S. PSA and a shrinkage of tumours following Lu177 PSMA therapy.

When would the doctor consider using this Therapy?

Lu PSMA Therapy is a very specific therapy and is used for managing metastatic Prostate Cancer or when Prostate Cancer is no longer responsive to other types of treatment.

What are the Treatment Schedules with Lu PSMA Therapy?

Most patients undergo three-four treatment cycles at intervals of 8-12 weeks. The number of cycles and the interim duration may vary between individuals depending on the response and interim assessments.

Why should I choose the nuclear medicine therapy center at Fortis Memorial & Research Institute (FMRI), Gurugram (Haryana, India)?

The Nuclear Medicine Therapy Centre at FMRI was one of the first institutes to offer Radio-ligand Therapy with Lu PSMA, and today, the center receives patients from the country and from across the world.

Lead Pb212 PSMA Therapy: A Promising New Treatment for Prostate Cancer

Summary (10 sec read)

Lead Pb212 PSMA therapy is a novel treatment for prostate cancer, targeting the prostate-specific membrane antigen (PSMA) overexpressed on cancer cells. Utilizing the radioactive isotope Lead-212 (Pb212), this therapy delivers targeted radiation to cancer cells, minimizing harm to healthy tissue. Pb212's short half-life ensures concentrated radiation delivery, enhancing treatment efficacy and reducing side effects. Clinical trials show promising results, with significant reductions in PSA levels and tumor size in patients with advanced prostate cancer. Pb212 PSMA therapy offers a potentially transformative, low-toxicity option, demonstrating high efficacy and promising future treatment potential for advanced prostate cancer.

Prostate cancer is one of the most common cancers among men, and despite advances in treatment, it remains a major health concern. The prostate-specific membrane antigen (PSMA) is a protein that is overexpressed on the surface of prostate cancer cells, making it a promising target for therapy. Lead Pb212 PSMA therapy is a new approach that uses a radioactive isotope to deliver targeted radiation directly to cancer cells, while sparing healthy tissue.

What is Lead Pb212 PSMA Therapy?

Lead Pb212 PSMA therapy is a type of targeted radiotherapy that uses a radioactive isotope called lead-212 (Pb212) to target prostate cancer cells. Pb212 has a short half-life, which means it emits radiation for a short period of time before it decays into a stable isotope. This allows it to deliver high doses of radiation directly to cancer cells, while minimizing exposure to healthy tissues.

The therapy works by attaching a PSMA-targeting molecule to Pb212, which is then injected into the patient's bloodstream. The molecule seeks out and binds to PSMA on the surface of cancer cells, allowing Pb212 to deliver radiation directly to the cancer cells.

Benefits of Lead Pb212 PSMA Therapy

Lead Pb212 PSMA therapy has several advantages over traditional treatments for prostate cancer, including:

Targeted Treatment: Pb212 PSMA therapy specifically targets cancer cells, sparing healthy tissues and reducing the risk of side effects.
High Efficacy: Pb212 emits alpha radiation, which is more effective at killing cancer cells than other types of radiation. This can lead to better outcomes for patients with advanced prostate cancer.
Shorter Treatment Course: Pb212 has a short half-life, which means that the treatment can be completed in a shorter time frame than traditional radiation therapy.
Low Toxicity: Pb212 has a lower toxicity than other types of radiation, making it a safer option for patients.

Clinical Trials and Results

Clinical trials have shown promising results for Pb212 PSMA therapy in the treatment of advanced prostate cancer. In a phase I trial, patients with metastatic castration-resistant prostate cancer (mCRPC) who had exhausted all other treatment options were treated with Pb212 PSMA therapy. The trial showed that Pb212 PSMA therapy was safe and well-tolerated, with no dose-limiting toxicities observed.

In a phase II trial, patients with mCRPC who had previously been treated with chemotherapy and androgen receptor-targeted therapy were treated with Pb212 PSMA therapy. The trial showed that Pb212 PSMA therapy was highly effective at reducing PSA levels and tumor size, with 82% of patients achieving a PSA response and 65% achieving a radiographic response.

Future of Pb212 PSMA Therapy

Lead Pb212 PSMA therapy has the potential to transform the treatment of advanced prostate cancer. Ongoing clinical trials are investigating its efficacy and safety in larger patient populations, and it is hoped that Pb212 PSMA therapy will become an important treatment option for patients with advanced prostate cancer.

In conclusion, Lead Pb212 PSMA therapy is a promising new treatment for prostate cancer that uses targeted radiation to deliver high doses of radiation directly to cancer cells while sparing healthy tissues. It has shown high efficacy and low toxicity in clinical trials, and has the potential to become an important treatment option for patients with advanced prostate cancer.

LEAD(Pb212) PSMA Therapy

Summary (10 sec read)

What is Lead Pb212 PSMA Therapy?

Benefits of Lead Pb212 PSMA Therapy

Clinical Trials and Results

Future of Pb212 PSMA Therapy

Consult Dr Ishita B Sen